Amicus Therapeutics (FOLD) Financials

View full company profile

$3 B

FOLD Mkt cap, 22-Jun-2018

Amicus Therapeutics EBIT (Q1, 2018)-56.2 M

Amicus Therapeutics Cash, 31-Mar-2018114.3 M

Amicus Therapeutics Financials

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Revenue	122.2 m	1.2 m		5 m	36.9 m
Revenue growth, %		(99%)	(100%)
Cost of goods sold				833 k	6.2 m
Gross profit				4.1 m	30.7 m
Gross profit Margin, %				83%	83%
R&D expense				104.8 m	149.3 m
General and administrative expense				71.2 m	88.7 m
Operating expense total				175.9 m	472.7 m
Depreciation and amortization					3.6 m
EBIT	(405.6 m)	(68.7 m)	(130.4 m)	(181.9 m)	(442 m)
EBIT margin, %	(332%)	(5613%)		(3669%)	(1197%)
Interest expense	46 k	1.5 m	1.6 m	5.4 m	17.2 m
Interest income	174 k	223 k	929 k	1.6 m	4.1 m
Pre tax profit					(449.1 m)
Income tax expense	3.5 m	1.1 m	1.1 m	3.7 m	165.1 m
Net Income	(378.5 m)	(68.9 m)	(132.1 m)	(200 m)

Source: SEC Filings

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q3, 2017
Revenue	39 k	456 k	475 k	293 k	456 k	475 k	293 k
Cost of goods sold										344 k	775 k	1.8 m
R&D expense	10.1 m	10 m	10 m	12 m	16.1 m	17.2 m	21 m	23.4 m	18.3 m	32.5 m	30.9 m
General and administrative expense	4.6 m	5.2 m	4.8 m	5.3 m	6.4 m	8.3 m	15.4 m	15.7 m	19.3 m	17.5 m	19.1 m
Operating expense total	15.2 m	16.1 m	14.7 m	17.1 m	24.1 m	26.9 m	38 m	43 m	48.5 m	46.7 m	55.4 m	284.3 m
EBIT	(15.1 m)	(15.6 m)	(14.3 m)	(16.8 m)	(24.1 m)	(26.9 m)	(38 m)	(43 m)	(48.5 m)	(44.9 m)	(52 m)	(275.2 m)
EBIT margin, %	(38808%)	(3426%)	(3003%)	(5739%)	(5276%)	(5672%)	(12985%)
Interest expense	7 k	355 k	374 k	377 k	372 k	338 k	17 k	945 k	1.1 m	1.5 m	4.3 m	4.4 m
Interest income	36 k	42 k	36 k	55 k	171 k	158 k	316 k	307 k	331 k	460 k	759 k	1.2 m
Income tax expense									453 k	253 k	(56 k)
Net Income	(14.6 m)	(15.9 m)	(14.6 m)	(17.1 m)	(24.3 m)	(27.1 m)	(37.8 m)	(43.7 m)	(51.1 m)	(46.7 m)	(55 m)	(214.8 m)

Source: SEC Filings

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Cash	43.6 m	24.1 m	69.5 m	187 m	49.1 m
Accounts Receivable				1.3 m	9.5 m
Inventories	5.5 m	2.9 m	2.6 m	3.4 m	4.6 m
Current Assets	88.3 m	154.6 m	216.6 m	340.1 m	392 m
Goodwill	11.6 m	11.6 m	197.8 m	197.8 m	197.8 m
Total Assets	127.6 m	210 m	908.4 m	1 b	627 m
Accounts Payable	10.2 m	16.3 m	32.2 m	185.5 m
Short-term debt
Current Liabilities	10.5 m	20.2 m	73.6 m	111 m	70 m
Long-term debt
Additional Paid-in Capital	423.6 m	568.7 m	917.5 m	1.1 b	1.4 b
Retained Earnings		(447.4 m)	(579.6 m)	(779.6 m)	(1.1 b)
Total Equity	45.8 m	122.2 m	347.8 m	360.2 m	352.9 m
Financial Leverage	2.8 x	1.7 x	2.6 x	2.9 x	1.8 x

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017	Q1, 2018
Cash	30 m	27.5 m	41.9 m	19.7 m	28.8 m	249 m	19.4 m	23.5 m	63.7 m	33.1 m	44.8 m	37.4 m	64.1 m	114.3 m
Accounts Receivable										864 k	1.9 m	3.8 m	6 m	10.8 m
Inventories									194 k	3.3 m	3.7 m	3.9 m	7.3 m	8.1 m
Current Assets	64.3 m	73.5 m	79.4 m	87.2 m	151.3 m	365 m	240.1 m	168.5 m	217.7 m	221.7 m	296.2 m	241 m	431 m	592 m
Goodwill		11.6 m	11.6 m	11.6 m	11.6 m	11.6 m	207.6 m	197.8 m	197.8 m	197.8 m	197.8 m	197.8 m	197.8 m	197.8 m
Total Assets	69.1 m	112.4 m	118 m	125.5 m	192.6 m	403.9 m	986.7 m	862.9 m	914 m	918.2 m	993.4 m	939 m	680.8 m	870 m
Accounts Payable	8.2 m	9.2 m	9.9 m	11.3 m	15.8 m	16.9 m	30.6 m	22.5 m	23.8 m	29 m
Current Liabilities	8.6 m	9.4 m	11.2 m	13.8 m	21 m	16.9 m	35.9 m	64.4 m	80.5 m	85.6 m	109.6 m	100.7 m	68.2 m	140.7 m
Total Liabilities														348.4 m
Additional Paid-in Capital	392.2 m	424.8 m	444.6 m	468.7 m	574.8 m	826.6 m	914.3 m	921.2 m	990 m	1 b	1.1 b	1.1 b	1.4 b	1.6 b
Retained Earnings			(409.1 m)	(426.2 m)	(471.7 m)	(498.9 m)	(536.7 m)	(623.3 m)	(674.3 m)	(721 m)	(834.6 m)	(882.7 m)	(994.4 m)	(1.1 b)
Total Equity	26.5 m	31.1 m	36.3 m	43.3 m	104 m	328.9 m	378.8 m	311.6 m	334.2 m	336.6 m	310.8 m	266.9 m	409.7 m	521.6 m
Financial Leverage	2.6 x	3.6 x	3.2 x	2.9 x	1.9 x	1.2 x	2.6 x	2.8 x	2.7 x	2.7 x	3.2 x	3.5 x	1.7 x	1.7 x

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Net Income	(59.6 m)	(68.9 m)	(132.1 m)	(200 m)	(284 m)
Depreciation and Amortization	1.7 m	1.5 m	1.8 m	3.2 m	3.6 m
Accounts Receivable				(1.4 m)	(7.7 m)
Inventories	(3.2 m)	2.3 m	308 k	(3.7 m)	(897 k)
Accounts Payable		6.2 m	15.5 m	7.1 m
Cash From Operating Activities	(45.8 m)	(51.7 m)	(100.1 m)	(150.5 m)	(215.5 m)
Purchases of PP&E	(695 k)	(238 k)	(4.8 m)	(6 m)	(4.5 m)
Cash From Investing Activities			(145.3 m)	(4.5 m)	(171.2 m)
Cash From Financing Activities		139.2 m	290.9 m	272.7 m	247.4 m
Interest Paid	30 k	1.2 m	605 k	3 m	7.4 m

Quarterly

USD	Q3, 2013	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017	Q1, 2018
Net Income	(47.4 m)	(15.9 m)	(30.6 m)	(47.7 m)	(24.3 m)	(51.4 m)	(89.2 m)	(43.7 m)	(94.7 m)	(141.4 m)	(55 m)	(103.1 m)	(214.8 m)	(49.9 m)
Depreciation and Amortization	1.3 m	412 k	808 k	1.2 m	508 k	861 k	1.3 m	673 k	1.4 m	2.3 m	823 k	1.6 m		969 k
Accounts Receivable										(863 k)	(512 k)	(2.2 m)	6 m	(1 m)
Inventories									(207 k)	(3.5 m)	(243 k)	(351 k)	7.3 m	(3.3 m)
Accounts Payable	(679 k)	(987 k)	(155 k)	1.2 m	(551 k)	459 k	14.1 m	(9.8 m)	(8.2 m)	(2.9 m)	(1.3 m)
Cash From Operating Activities	(37.7 m)	(10.2 m)	(22 m)	(37.2 m)	(21 m)	(43.6 m)	(64.6 m)	(44.9 m)	(77.7 m)	(118.5 m)	(49.8 m)	(91.8 m)	(141.7 m)	(49.5 m)
Purchases of PP&E	(645 k)	(40 k)	(132 k)	(192 k)	(753 k)	(1.4 m)	(2.2 m)	(2.9 m)	(4.6 m)	(5.5 m)	(732 k)	(2.3 m)
Cash From Investing Activities		(5.8 m)	2.1 m	(27.3 m)		31.3 m	(230.7 m)			(39.9 m)	(92.4 m)	(48.9 m)	(222.8 m)	(182.6 m)
Cash From Financing Activities		(85 k)	18.2 m	40.5 m	4.1 m	237.2 m	290.7 m		82.8 m	122.4 m	(95 k)		240.6 m	296.6 m
Interest Paid	24 k	208 k	537 k	864 k	209 k	605 k	605 k	209 k	276 k	284 k	12 k	3.7 m	3.7 m	12 k
Free Cash Flow														(50.3 m)

Report incorrect company information

View Amicus Therapeutics profile

Competitors

Mast Therapeutics

Health - Public

Health - Public

Health - Public

Health - Public

Compare competitors